Resistance of ovarian mucinous adenocarcinoma to standard chemotherapy with paclitaxel and carboplatin is associated with poor prognosis, and an effective treatment is needed. The present study aimed to identify an effective chemotherapy for ovarian mucinous adenocarcinoma. Five human ovarian mucinous adenocarcinoma cell lines (MN-1, OMC-1, RMUG-L, RMUG-S, TU-OM-1) were used in this study. Sensitivity of the cells to the anticancer agents was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and we assessed drug sensitivity by calculating the assay area under the curve for each agent. Several studies show that MAC is often diagnosed at an early stage, and therefore, confers a relatively good prognosis.
M ucinous adenocarcinoma of the ovary (MAC) is the third most common type of epithelial ovarian cancers (EOC), comprising 10 to 12% of EOC. MAC appears to have a distinctly different clinical behavior from that of other EOC. (1) (2) (3) Several studies show that MAC is often diagnosed at an early stage, and therefore, confers a relatively good prognosis. (1) (2) (3) However, advanced MAC has a poorer prognosis than other histopathologic subgroups. (4) (5) (6) MAC's low response (26-42%) to conventional platinum-based chemotherapy is associated with poor prognosis because chemosensitivity is one of the main prognostic factors for patients with advanced EOC. (4) (5) (6) (7) (8) (9) Although MAC is known to be resistant to platinum-and taxane-based chemotherapy, patients with EOC are usually treated with this first-line chemotherapy regimen. A novel treatment strategy for advanced MAC is urgently needed.
Recently, new agents for EOC have been developed, including oxaliplatin (L-OHP), etoposide (VP-16) and camptothecin . (10) L-OHP (1R,2R-diaminocyclohexane oxalatoplatinum [II] ) is a 1,2-diaminocyclohexane (DACH) platinum compound with a partial lack of cross-resistance to platinum analogs, cisplatin (CDDP) and carboplatin. (11) (12) (13) VP-16, which inhibits the activity of DNA topoisomerase II, is used as a second-line treatment for patients with platinum-resistant EOC. (14) CPT-11, which inhibits topoisomerase I by forming stable topoisomerase I-DNA cleavable complexes (15) has been studied in relapsed EOC. (16) The thymidylate synthase inhibitor, 5-fluorouracil (5FU), was reported to be an active agent for recurrent EOC. (17, 18) We conducted the present study to identify an effective chemotherapy for MAC.
Materials and Methods
Cell lines and cell cultures. The five MAC cell lines used in the present study (MN-1, OMC-1, RMUG-L, RMUG-S, TU-OM-1) were obtained as follows: MN-1 from Dr Yasuhiko Kiyozuka (Kansai Medical University, Osaka, Japan), OMC-1 from Dr Tsuyoshi Saito (School of Medicine, Sapporo Medical University, Sapporo, Japan), and RMUG-L and RMUG-S from Dr Daisuke Aoki (Keio University, Tokyo, Japan). TU-OM-1 was established by our department. These cell lines were maintained in D-MEM/ Ham's F-12 medium (Wako, Osaka, Japan) with 10% fetal bovine serum, 100 IU/mL penicillin and 50 μm/mL streptomycin in a humidified atmosphere containing 5% CO 2 at 37°C.
Dose-response studies. The sensitivity of the cell lines to the anticancer agents was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-dyphenyltetrazolium bromide (MTT) assay. (19) Briefly, cells were diluted with culture medium to the seeding density of 1-3 × 10 4 cells/mL, plated on 96-well tissue culture plates at 100 μL/well (Sumitomo Bakelite, Tokyo, Japan), and incubated at 37°C overnight. The next day, the cells were treated continuously with 20 μL of various concentrations of the anticancer agents to obtain a dose-response curve for each agent. Each drug concentration was as follows: 1-100 μM CDDP (Sigma, St. Louis, MO, USA), 0.1-50 μM 5FU (Wako), 1-100 μM L-OHP (Wako), 0.01-10 μM paclitaxel (PTX) (Sigma), 0.01-10 μM 7-ethyl-10-hydroxycamptothecin (SN38) (Yakult Honsha Co., Tokyo, Japan), which is an active metabolite of CPT-11, and 0.1-100 μM VP-16 (Sigma).
After incubation for 72 h, 10 μL MTT solution (5 mg/mL) (Sigma) was added to each well, and the plates were incubated for another 4 h. At the end of that incubation, 100 μL 1 To whom correspondence should be addressed. E-mail: itamochi@grape.med.tottori-u.ac dimethylsulfoxide (Sigma) was added to each well to solubilize the MTT formazan product. Absorbance at 570 nm was measured with a microplate reader (model 550; Bio-Rad, Richmond, CA, USA). Growth inhibition was calculated as the percentage of viable cells compared with untreated cultures.
L-OHP or CDDP was combined with 5FU, PTX, SN38 and VP-16 at a fixed ratio that spanned the individual (IC 50 ) of each drug. The 50% inhibitory concentration of a substance (IC 50 ) was determined on the basis of the dose-effect curves, using a standard MTT assay. Median-effect plot analyses and calculation of the combination index (CI) were analyzed by the method of Chou and Talalay. (20) CalcuSyn software (Biosoft, Cambridge, UK) was used to analyze data from the MTT assays in which cells were exposed to agents alone or in combination with anticancer drugs. The computer program provides a measure of the combined agents in an additive or synergistic manner. Chou and Talalay (20) defined CI, which assesses synergism (CI < 0.9), additive behavior (CI = 0.9-1.1) or antagonism (CI > 1.1).
To assess drug sensitivity, the assay area under the curve (AUC) was calculated by means of the following formula: initial concentration × t 1/2 × 1.44{1 -exp(−0.693 × 72/t 1/2 )}. Initial concentration was determined based on the IC 50 of each agent in the present study and t 1/2 is the in vitro half-life of the drug at 37°C. (21) The half-lives of CDDP and VP-16 are 18.5 and 60 h, respectively. (22) We confirmed that the half-life of L-OHP was 23 h. Those of 5FU, PTX and SN38 were reported as stable in serum-containing medium at 37°C in the presence of 5% CO 2 ; therefore, the assay AUC of those drugs were calculated as the drug concentration × 72 h. (23) The assay AUC was then compared with the clinically achievable AUC with a standard dose of each drug. If the calculated assay AUC was less than the clinically achievable AUC, the drug was defined as sensitive.
Western blot analysis. Cells were washed twice with phosphatebuffered saline (PBS) and then lyzed in lysis buffer (50 mM Tris-HCl, 125 mM NaCl, 0.1% Nonidet P-40, 5 mM ethylenediaminetetraacetic acid, 50 mM NaF, 0.1% phenylmethylsulfonyl fluoride, protease inhibitors (Protease Inhibitor Cocktail Set I; Calbiochem, Darmstadt, Germany). Protein concentrations were measured against a standardized control by using a protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). A total of 50 μg protein was separated by electrophoresis on a 10% polyacrylamide gel and transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The specific antibodies used were rabbit anti-Akt antibody (1:1000 dilution; Cell Signaling Technology, Beverly, MA, USA), rabbit antiphospho-Akt (serine 473) antibody (1:1000 dilution; Cell Signaling Technology), rabbit anti-MEK1 antibody (1:1000 dilution; Cell Signaling Technology), rabbit antiphospho-MEK1 (threonine 286) antibody (1:500 dilution; Cell Signaling Technology), rabbit anti-Bcl2 antibody (1:1000 dilution; Cell Signaling Technology), rabbit anti-Bcl-xL (1:1000 dilution; Cell Signaling Technology), mouse anti-ERCC1 antibody (1:100 dilution; Abcam), mouse anti-XPF antibody (1:100 dilution; Abcam), mouse anti-XRCC1 antibody (1:500 dilution; Abcam) and mouse anti-Actin antibody (1:1000 dilution; Sigma). These were visualized with secondary antirabbit or antimouse IgG antibody coupled with horseradish peroxidase, using enhanced chemiluminescence according to the manufacturer's recommendation.
Annexin V staining. The Annexin V-PE Reagent (BioVision Research Products, Mountain View, CA, USA) was used to assess apoptosis in terms of the externalization of phosphatidylserine residues, according to the specifications of the manufacturer. Briefly, cells were washed twice with cold PBS and once with 1 × Annexin V binding buffer (10 mmol/L HEPES/NaOH [pH 7.4], 140 mmol/L NaCl, 2.5 mmol/L CaCl 2 ). The cells were then stained with Annexin V-PE diluted 1:10 in 1 × Annexin V binding buffer for 15 min at room temperature. Finally, the cells were washed with 1 × Annexin V binding buffer, then 500 μL 1 × Annexin V binding buffer was added to each well and the cells analyzed with a flow cytometer (Olympus, Tokyo, Japan).
Ovarian cancer xenograft model. The present study was carried out at the Laboratory Animal Research Center under the control of the animal research committee, in accordance with the Guidelines for Animal Experimentation in the Faculty of Medicine, Tottori University, Yonago, Japan. For these experiments, TU-OM-1 cells in log-phase growth were trypsinized, washed twice with PBS and centrifuged. Viable cells were counted, then 2 × 10 6 viable cells (in 0.5 mL PBS) were injected under aseptic conditions into the peritoneal cavities of female nude mice. Mice were then assigned randomly to one of four groups (five mice per group) and treatment was started five days later as follows. Group 1, intraperitoneal (i.p.) PBS weekly for 3 weeks; group 2, i.p. L-OHP weekly (12.5 mg/kg per injection) for 3 weeks; group 3, i.p. 5FU weekly (25 mg/kg per injection) for 3 weeks; and group 4, i.p. L-OHP and with 5FU weekly for 3 weeks.
Statistical analysis. Statistical analyses were carried out using the GraphPad Prism Version 5 program (GraphPad Software, San Diego, CA, USA). Data are presented as mean ± SD. Survival distributions were calculated using the Kaplan-Meier method, and the significance of apparent differences in survival distribution between groups was tested with log-rank tests. P < 0.05 was considered statistically significant.
Results
Sensitivity to anticancer agents. The IC 50 values of each cell line for anticancer agents are shown in Table 1 . The IC 50 s ranged from 3.78 to 49.78 μM for CDDP, from 0.68 to 29.27 μM for 5FU, from 2.21 to 39.58 μM for L-OHP, from 0.29 to 0.83 μM for PTX, from 0.02 to 4.18 μM for SN38 and from 0.31 to 38.72 μM for VP-16, indicating that these cell lines showed various sensitivities to anticancer agents. When the assay AUC was compared with clinically achievable AUC using a standard dose of each drug, two of five cell lines (MN-1, TU-OM-1) were defined as sensitive to L-OHP, 5FU or VP-16 and only one (TU-OM-1) was sensitive to SN38. All cell lines were resistant to CDDP and PTX (Table 2) .
Combination effects of oxaliplatin and 5-fluorouracil or etoposide.
We then examined cell proliferation after treating with both L-OHP and 5FU or VP-16, because these drugs were effective for two of five MAC cell lines. When L-OHP was combined with 5FU, the CI values at an effective dose of 50 (effective dose means the percentage of inhibition of cell growth using the drug combinations in the experiment) were less than 1.1 for all of the five MAC cell lines. The CI values were less than 1.1 for only one cell line when L-OHP was combined with VP-16 ( Fig. 1) . Thus, combination treatment of L-OHP with 5FU might have more cytotoxic effect on MAC cells than that with VP-16. Next, to test whether combining L-OHP with 5FU would suppress cell growth at the concentrations calculated by clinically achievable AUC, we treated MAC cell lines with 3.1 μM L-OHP and 5.8 μM 5FU. Seventy-two hours after exposure, growth inhibition was measured using the MTT assay. When L-OHP was combined with 5FU, more than 50% of cell growth suppression was observed in four of five MAC cell lines (Fig. 2a) . The number of Annexin V-positive cells also increased additively 24 h after treating with L-OHP and 5FU in all cell lines (Fig. 2b,c) . 5FU reduced cell viability and enhanced apoptosis in vitro, we examined the effect of combination treatment of L-OHP and 5FU on survival in a xenograft model of MAC. Mice treated with both L-OHP and 5FU survived significantly longer than those treated with PBS, 5FU or L-OHP (P < 0.005) (Fig. 3) . The median survival times were 188 days for L-OHP with 5FU treatment, 83 days for PBS treatment, 96 days for 5FU treatment and 124 days for L-OHP treatment. This finding indicates that L-OHP combined with 5FU resulted in prolonged survival in nude mice bearing TU-OM-1 cells.
Protein expression of cell-survival and DNA repair pathways. The protein expression levels of Akt, phosphorylated (p) Akt, MEK, pMEK, Bcl2 and Bcl-X L were not related to the sensitivity of anticancer agents tested (Fig. 4a) . Among DNA repair proteins, higher ERCC1 expression was observed in L-OHP resistant cells (OMC-1, RMUG-L, RMUG-S) (Fig. 4b) .
Next, we examined the protein expression level of ERCC1 at 24 h after treatment with L-OHP and/or 5FU. ERCC1 expression was suppressed after treating with 5FU with or without L-OHP in RMUG-L and TU-OM-1 cells (Fig. 5a) . Similar results were obtained in the other three cell lines. Furthermore, Western blot analysis of tumor tissues verified that 5FU down-regulated ERCC1 protein expression in tumor cells (Fig. 5b) .
Discussion
Determining cellular sensitivity is difficult due to the wide range of IC 50 to anticancer agents. Additionally, protein binding of drug and drug stability in the culture medium are important pharmacodynamic factors. Assay AUC is a useful method to predict cellular sensitivity to anticancer agents, which correlates to clinical response. (24, 25) In the present study, we calculated assay AUC to assess drug sensitivity and found that two (MN-1, TU-OM-1) of five cell lines were sensitive to VP-16, 5FU and L-OHP, and one cell line (TU-OM-1) to SN38, whereas all cell lines were resistant to CDDP and PTX, which have been used as a standard chemotherapy for EOC. Furthermore, combination treatment of L-OHP with 5FU has more cytotoxic effect on MAC cells than that of L-OHP with VP-16 and suppressed cell proliferation more than 50% in four of five cell lines at the same concentrations calculated by clinically achievable AUC. We confirmed the combination effect of L-OHP and 5FU in a MAC xenograft model. Combining L-OHP and 5FU prolonged the survival of these mice compared with those treated with L-OHP or 5FU alone. These data provide clear evidence that this combination therapy may be effective for MAC. To our knowledge, this is the first study to show that the combination of L-OHP and 5FU is effective for MAC both in vitro and in vivo. L-OHP is a third-generation platinum compound with a spectrum of activity and toxicity that differs from CDDP by the presence of a DACH ligand, although L-OHP and CDDP act theoretically by the same mechanism of action. (26, 27) Like other DACH platinum compounds, L-OHP has different sensitivity profiles in a broad range of cancer cell lines, and has shown activity in a number of cell lines, including ovarian cancer, that exhibit intrinsic or acquired resistance to CDDP. (11) (12) (13) We also found two of five MAC cell lines to be sensitive to L-OHP, although all cell lines were resistant to CDDP. Several explanations as to the mechanisms for this lack of cross-resistance have been proposed. In contrast to CDDP, cellular accumulation of L-OHP seems to be less dependent on copper transporter 1 (CTR1), which is the major copper influx transporter; (28) a lower intracellular drug concentration and fewer platinum (Pt)-DNA adducts are sufficient for L-OHP to exert its cytotoxicity; (29) and mismatch repair protein does not bind to DACH-Pt-DNA adducts. (30) Recently, several reports revealed the importance of the nucleotide excision repair (NER) process in the sensitivity to L-OHP and CDDP. (31, 32) Furthermore, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1) is essential for NER process, and its mRNA or protein expression levels have been involved in L-OHP sensitivity. (31) (32) (33) Indeed, we observed high protein expression levels of ERCC1 in L-OHP-resistant cell lines. These results suggest that ERCC1 protein expression level may be related to L-OHP sensitivity in MAC cells.
In this study, the combination of L-OHP and 5FU revealed synergistic or additive effects in all MAC cell lines. (20) We next attempted to elucidate the reason why this combination of L-OHP and 5FU contributes to the increasingly cytotoxic effect for MAC cells, and found that the protein expression levels of ERCC1 were down-regulated after treatment of 5FU both in vitro and in vivo. Ojima et al. (34) reported that 5FU post-treatment gradually inhibited mRNA expression of ERCC1 in colon cancer cell lines. Suppression of the protein expression of ERCC1 by 5FU may affect recombination DNA repair efficiency. Therefore, these results suggest that the down-regulation of ERCC1 protein expression by treating with 5FU may enhance the cytotoxic effects of L-OHP.
We found that the combination treatment of L-OHP and 5FU had marked cytotoxic effects on MAC cells, even on cell types known to be resistant to conventional platinum-and taxanebased chemotherapy. We also found that ERCC1 expression levels probably affected the cytotoxic effects of L-OHP, and this effectiveness may be related to down-regulation of ERCC1 protein expression by 5FU exposure. Therefore, we concluded that this combination treatment is worth exploring as a treatment modality for MAC. Our next step is to evaluate the ability of ERCC1 expression levels to predict response to chemotherapy in clinical studies. Currently, a phase III clinical trial of L-OHP and capecitabine, which is a prodrug of 5FU, versus carboplatin and PTX in MAC, is underway at the Gynecologic Oncology Group (GOG). We hope that this combination therapy will prolong the survival of patients with advanced MAC.
